4 results
Main objectives: The main aim of this study is twofold. We aim to (1) investigate whether rivastigmine can be used as a novel treatment to reduce ECT-induced interictal delirium and (2) to gain further insight into differences in determinants…
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Part I: Evaluate the safety and tolerability of selinexor at 3 different dose levels in combination with bortezomib/dexamethasone & determine recommended dose level (RDL) of selinexor for Part IIPart II: Evaluate the efficacy of the…
The primary objective of the study is to compare the PFS of SPd versus EloPd in patients with MM who have received 1 to 4 prior anti-MM lines of therapy and never received pomalidomide, selinexor, or elotuzumab. Patients must have had prior…